NutraLife Biosciences (NLBS) Announces New Phytocannabinoid Rich (PCR Pure) Water Enhancing Product Line

NutraLife Biosciences, Inc. (the “Company” or “NutraLife”) (OTCQB: NLBS) to launch a new line of Phytocannabinoid rich (PCR) water enhancing drops under its new in-house brand PCR Pure.  NutraLife’s new CBD water enhancers will initially be available in four flavors, strawberry, grape, coconut and watermelon. Each 2 oz. bottle will contain 15 servings and have 20 mg per serving or 300 mg per bottle of PCR hemp extract.  The new water enhancers are infused with the extract and can be added to water or other beverages to help support overall health and wellness.

NutraLife’s water enhancers will be manufactured at its  Coconut Creek facility in accordance with Good Manufacturing Practices (GMP) under the direction of Edgar Ward, the Company’s Chief Executive Officer. NutraLife’s products are tested for potency and purity by its in-house laboratory chemists. The Company’s products also undergo third-party testing to ensure they do not contain contaminants such as heavy metals, pesticides, and solvents.

NutraLife manufacturers and distributes thirteen different core formulations which it modifies to meet the specifications of its private label customers. The Company provides approximately 50 different variations of its core formulations. In addition to NutraLife’s CBD water enhancers, NutraLife’s products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products for daily health and wellness uses.

NutraLife’s  CBD water enhancers are designed to provide a convenient daily dose of Phytocannabinoid rich hemp extract for on the go. NutraLife’s water enhancing drops will be coming soon to online retailers as well as the Company’s website at PCRPure.com.

About the Company

Nutralife Biosciences, Inc. operates a multifaceted life sciences company. For more than 6 years the Company has manufactured and distributed private label and branded nutraceutical and wellness products. The Company launched its hemp-based CBD products in 2017. Through its subsidiaries, Precision Analytic Testing, Inc., and PhytoChem Technologies, Inc., NutraLife provides bulk material analytical, identity, potency and purity testing of raw hemp, hemp cultivation, raw bulk material extraction and processing.

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NLBS” or the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions.  The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL  33073

Telephone 888-509-8901
www.NutraLifeBioSciences.com
www.PCRPure.com

NutraLife Biosciences, Inc. Enters Into Joint Venture with Henning Trading LLC to Cultivate and Process Hemp for 2019 U.S. Grow Season

Coconut Creek, FL – (NewMediaWire) – April 11, 2019 –  NutraLife Biosciences, Inc. (the “Company” or “NutraLife”) (OTCQB: NLBS) announces that its wholly-owned subsidiary, PhytoChem Technologies, Inc. (“PhytoChem”) has entered into a joint venture with Henning Trading LLC (“Henning Trading”). NutraLife and Henning plan to cultivate, harvest and process hemp initially in Wisconsin for the 2019 grow season. NutraLife recently announced that it had received licenses from the state of Wisconsin to grow and process hemp.

 

NutraLife’s joint venture with Henning Trading will be under the direction of NutraLife’s Chief Executive Officer and President, Edgar Ward, and Henning’s President, John Henning Jr., its Chief Operating Officer, Adam Bilbrey, its Chairman, John Bilbrey and its sales director, Michael Ward.  Henning and PhytoChem plan to pursue opportunities for the cultivation, harvesting, processing and distribution of high-quality bulk and raw bulk material supply of Phytocannabinoid CBD rich hemp finished goods. In addition, NutraLife and Henning Trading will explore participation in the hemp seed propagation, fiber and grain markets.

 

“We are pleased to have finalized our agreement with Henning Trading and look forward to working with John Henning and Adam Bilbrey to pursue the Company’s vertical positioning within the hemp industry. We look forward to continued growth and new opportunities in the Nutraceutical, Hemp and Life Sciences markets as we enter the second quarter of 2019,” said Edgar Ward, CEO and Founder of NutraLife.

 

About NutraLife BioSciences

NutraLife was founded by Edgar Ward in 2010 as NutraFuels, Inc. and since that time he has served as its Chief Executive Officer, President and Director. Under Mr. Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers thirteen different core formulations which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products for sleep support and weight loss packaged under the customer’s brand names.

 

About Henning Trading LLC

Henning Trading LLC (“Henning Trading” or “Henning”) was founded in 2018 by John Henning Jr., Adam Bilbrey, and Henning’s Chairman, J.P. Bilbrey. J.P. recently retired as Chairman, CEO and President of The Hershey Company (HSY).  Henning was founded to provide logistics, sourcing and extraction production for industrial hemp.

 

John Henning, Jr. is a graduate from the University of Mississippi with a Bachelor of Science.  John owns and operates Henning farm in Kingman, Kansas that has been in the Henning family for 4 generations. Using the experience and knowledge he gained from his family’s farming operations, John entered the industrial hemp market focusing on growing methods and cultivation and is considered a master grower.

 

Adam Bilbrey is a co-founder and President of Rental Geek, Inc, a company that revolutionized the off-campus student real estate rental market. Adam is also a co-founder and active officer at Famous Vape, Inc and a co-founder and majority partner at iMed Delivered, Inc.  Adam holds a Master’s in Business Administration and Bachelor of Science in Business from Kansas State University.

 

Mr. John P. Bilbrey, also known as J.P. serves as Member of Board of Directors at Elanco Animal Health Incorporated since March 13, 2019. He was Non-Executive Chairman of The Hershey Company since April 2, 2015 until May 02, 2018. Mr. Bilbrey served as the Chief Executive Officer and President of The Hershey Company from May 17, 2011 to March 1, 2017. Mr. Bilbrey served as the Chief Operating Officer and Executive Vice President of The Hershey Company from November 2, 2010 to May 17, 2011. He served as the President of North America at The Hershey Company from December 2007 to November 2010 and served as its Senior Vice President from November 2005 to November 2010. Mr. Bilbrey has more than 20 years of international consumer sales and marketing experience at Procter & Gamble, which included several overseas assignments. He served as the President of International Commercial group from November 2005 to December 2007 and Senior Vice President of Hershey International from 2003 to December 2007 at The Hershey Company. Mr. Bilbrey served as an Executive Vice President of Sales of Mission Foods since 2003; and served as the President, Chief Executive Officer and Executive Vice President of Retail Sales of Danone Waters of North America, Inc., a division of Groupe Danone, Paris since 2001; Owner and Operator of Commercial Cattle Operations of Bilbrey Farms and Ranch since 1999 and Director of Corporate Sales, Taiwan – Procter & Gamble Company since 1998. He served as an Independent Director of McCormick & Company, Incorporated from November 2005 to May 27, 2015. Mr. Bilbrey has been an Independent Director at Colgate-Palmolive Company since March 13, 2015. He was a Director of The Hershey Company since June 2011 until May 02, 2018. He holds a Bachelor’s Degree in Psychology from Kansas State University.

 

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”) and Henning Trading, LLC. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to cultivate, harvest and process Hemp with Henning Trading will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applies.

NutraLife Biosciences, Inc. (OTCQB: NLBS) Provides Shareholder Update

NutraLife Biosciences, Inc. (the “Company” or “NutraLife”) (OTCQB: NLBS) is pleased to announce revenue growth of approximately 107.3% in 2018, the filing of its revenue growth of approximately 107.3% in 2018, the filing of its Annual Report on Form 10-K and audited financial results. Highlights from the Company’s financial results reported in its Form 10-K for the year ended December 31, 2018 include:

  • Sales increased to $3,711,327 for the year ended December 31, 2018 compared to $1,790,168 for the year ended December 31, 2017, an increase of approximately 107.3%.
  • Cost of sales was $2,211,039 compared to $1,055,042 for the years ended December 31, 2018 and 2017, respectively, or a 109.6% increase.
  • Net Loss decreased approximately 91.3% to $2,074,537 in the year ended December 31, 2018 from $23,629,117 in 2017.
  • Gross margin for the year ended December 31, 2018 was $1,500,288, a 104.1% increase over the year ended December 31, 2017.
  • Sales of CBD products increased from approximately $1,380,000 for the year ended December 31, 2017 to $2,400,000 for the year ended December 31, 2018 representing 77% and 78% of our revenues for such periods.

“We are pleased to announce our audited financial statements with improved quarter-to-quarter and annual growth as our revenue grew to $3,711,327 for the year ended December 31, 2018, an increase of approximately 107.3% over 2017. We look forward to continued growth and new opportunities in the Nutraceutical, CBD and Life Sciences markets as we enter the second quarter of 2019.,” said Edgar Ward, CEO and Founder of NutraLife.

2018 Operational Overview

NutraLife’s manufacturing facility has been registered with the Food and Drug Administration and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. The Company’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. The Company offers thirteen (13) different core formulations which it modifies to meet the specifications of its private label customers. NutraLife BioSciences provides approximately 50 different variations of its core formulations. The Company’s private label products include CBD-infused oral sprays, tinctures, pet drops, pain balms, and face creams, and nutraceutical oral spray products for sleep support and weight loss packaged under the customer’s brand names.

New Facility

In April 2017, the Company secured a 20,000 square foot manufacturing facility, which is being custom built to accommodate high-speed high capacity manufacturing of the Company’s products. The Company expects the build-out to be complete and production to begin this summer. The facility will provide more than 9,000 square feet of manufacturing with a total of 17,000 square feet of processing space to meet the increased demand for the Company’s products and services.

Subsidiaries

The Company recently established its wholly owned subsidiaries which are now engaged in operations:

  • Precision Analytic Testing, LLC, a Florida limited liability company (“PAT”) formed on May 11, 2017
  • NutraDerma Technologies, Inc, (“NutraDerma”) a Florida corporation formed on January 28, 2019
  • PhytoChem Technologies, Inc., a Florida corporation (“PhytoChem”) formed on February 4, 2019

Recent Developments

In November of 2018, PAT began providing bulk material analytical, identity, potency and purity testing of raw industrial hemp.

In December of 2018, the U.S. Food and Drug Administration completed an evaluation of three generally recognized as safe (GRAS) notices for hemp seed derived food ingredients. The FDA stated that hulled hemp seed (GRN765), hemp seed protein powder (GRN771), and hemp seed oil (GRN778) are GRAS under their intended conditions of use. Our CBD products are made from seeds and mature stalks of hemp and contain only trace amounts of THC, we believe they qualify as GRAS products.

In January of 2019, NutraDerma acquired the patent for a natural dermal skin patch that is designed to prevent mosquito and other insect bites.  We recently secured manufacturing through a third party and we expect to launch the product in time for the 2019 mosquito season. We have secured production and are in the process of conducting a research study for efficacy. We are also exploring international distribution of the product.

In April of 2019, the Company completed development of its PCR Derma Patch. The PCR Derma Patch delivers 40 mg of Phytocannabinoid rich hemp extract that can last up to four days.

In March of 2019, the Company licensed its technology for a unique system for pharmaceutical grade delivery of testosterone into the human body to a licensed pharmacist, Orlando Pharmacy. The Company expects the first pharmaceutical products using its technology to be available within 30 days.

In March of 2019, we received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state. The Company plans to develop efficient, cost reducing growing systems and techniques along with processing technologies for industrial hemp and other botanicals.

In January, the Company completed development of its branded Micro Twist Shots. The products will be sold under the Company’s NutraHempCBD brand. The Company plans to launch the products before the end of April 2019. Micro Twist Shots provide a single dose of the Company’s 5 signature daily health and wellness formulations that include CBD.

Future Strategy

We intend to grow our business by pursuing the following strategies:

  • We plan to continue to brand ourselves as a High-Quality GMP Compliant manufacturer of industrial hemp derived CBD products. Many manufacturers of CBD based products do not operate in compliance with GMP standards. All of our CBD products are tested at multiple stages of the production process to ensure product quality and a THC content of less than 0.3%.
  • We will seek to increase sales to our existing customers by offering additional products. Certain customers of ours began their relationship with us by purchasing only one of our products. Since these initial purchases, we have been able to expand our sales to such customers by offering multiple newly developed high-quality effective products. This strategy has enabled us to expand our product lines and sales to our new and existing customers. Our range of products enables us to pursue many cross-selling opportunities.
  • We seek to increase sales to customers by offering products in categories outside of our traditional product offerings. For example, in November of 2018, through our wholly owned subsidiary PAT, we began providing bulk material analytical, identity, potency and purity testing of raw hemp. In the first quarter of 2019, we took the first steps to commercialize a patented all natural dermal skin patch that prevents mosquito and other insect bites. Through our wholly owned subsidiary PhytoChem, we plan to provide hemp cultivation and raw bulk material extraction and processing starting with our licenses in the state of Wisconsin.
  • We plan to leverage our sales, reputation for quality all natural products to expand our customer base to other private label customers within the life sciences, CBD and Nutraceutical markets.

The financial information contained in this press release is qualified in its entirety by the audited financial statements and financial statement notes included in the Company’s Form 10-K for the year ended December 31, 2018, filed with the Securities & Exchange Commission on April 2, 2019.

Forward-Looking Statements

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. NutraLife BioSciences, Inc. (“NLBS” or the “Company”) has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL  33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com

10K 2018 Financials NLBS 1252

Summary: NutraLife BioSciences, Inc. (“NLBS” or the “Company”), a manufacturer and distributor of CBD and nutritional spray products and tinctures announces its financial results for the year ended December 31, 2018 with revenue of $3,711,327 compared to $1,790,168 for the year ended December 31, 2017.

NutraLife Biosciences Inc. (“NutraLife Biosciences” or “NLBS”), (OTC Markets OTCQB: NLBS), a developer, manufacturer and distributor of nutraceutical and CBD products today announced the filing of its Form 10-K and financial results for the fiscal year ended December 31st, 2018.

Highlights from the Company’s financial results reported in its Form 10-K for the year ended December 31, 2018 include:

  • Sales increased to $3,711,327 for the year ended December 31, 2018 compared to $1,790,168 for the year ended December 31, 2017, an increase of approximately 107.3%.
  • Cost of sales was $2,211,039 compared to $1,055,042 for the years ended December 31, 2018 and 2017, respectively, or a 109.6% increase.
  • Net Loss decreased approximately 91.3% to $2,074,537 in the year ended December 31, 2018 from $23,629,117 in 2017.
  • Gross margin for the year ended December 31, 2018 was $1,500,288, a 104.1% increase over the year ended December 31, 2017.
  • For the year ended December 31, 2018, Loss from Operations decreased approximately 90.6% from 2017 ($1,906,044 compared to $20,289,624).
  • Cash provided by financing activities for the year ended December 31, 2018 decreased approximately 19.4% from 2017.
  • General and Administrative Expenses increased for the year ended December 31, 2018 to $2,070,714 or approximately 17.6% from $1,760,148 for the year ended December 31, 2017.
  • New Debt increased in the year ended December 31, 2018 to $480,000.
  • The annual loss for the year ended December 31, 2018 includes approximately $1,200,000 of non-cash charges relating to the conversion of debt and shares issued for services.

“NutraLife BioSciences, Inc. (“NLBS”, “we”, or “us”) is pleased to report its 2018 year-end financials and announced that its revenues have improved more than approximately 107% over 2017,” said Edgar Ward, NLBS’s CEO. “The notable increase in our revenue is a direct result of increased business and reorder production over this past year. NLBS’s net loss reflects non-recurring additional paid in capital as non-cash and is in the form of stock issued at fixed prices for debt conversions and for services rendered throughout the year. NLBS has entered phase two of its build out of its new 20,000 square foot manufacturing facility in Deerfield Beach, Florida. We look forward to the increased capacity and efficiencies that will come with our new state of the art facility. We plan to move into the new facility by the end of the second quarter.”

The financial information contained in this press release is qualified in its entirety by the audited financial statements and financial statement notes included in the Company’s Form 10-K for the year ended December 31, 2018, filed with the Securities & Exchange Commission on April 2, 2019.


Forward Looking Statements

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. NutraLife BioSciences, Inc. (“NLBS” or the “Company”) has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraLife Biosciences Encouraged By CVS Health Corporation’s Decision to Distribute CBD at 800 Stores in the U.S.

Summary: CVS Health Corp. announces it will carry cannabidiol, also known as CBD, the non-psychoactive derivative of hemp in about 800 stores across the US.

NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) notes current trends in the retail space including CVS Health Corp.’s announcement that it will carry products containing CBD derived from hemp in about 800 of its U.S. drugstores.

NutraLife announces new additions to its NutraHempCBD product line with a micro shot CBD twists in 5 of its signature formulations including; sleep, pain, stress, weight, and sleep. The NutraHempCBD twists are designed for on-the-go convenience and set to launch on April 15 of this year.

“It is encouraging to see that mainstream retail giants like CVS are offering hemp derived CBD products to consumers,” said Edgar Ward, Founder and Chief Executive Officer of NutraLife Biosciences.

NutraHempCBD is in the last stages of development of its CBD micro shot twist products offering a single serving of CBD plus other clinically tested ingredients for daily health and wellness applications. The launch of the CBD micro shot twists in its 5 signature formulations demonstrate evolving and innovative retail-ready nutraceutical and industrial hemp CBD products.

Since 2013, the Company has engaged in the manufacturing and distribution of nutraceutical products for both branded and private label sales. In 2017, the Company launched its industrial hemp CBD products for private label sales and its own NutraHempCBD brand. The Company’s products are sold at a variety of retailers including drugstores.

According to reports, executives on Curaleaf’s earnings conference call said CVS would begin to carry its Curaleaf hemp lotions and transdermal patches in about 800 stores across 10 U.S. states. Chief Executive Officer of CVS, Joe Lusardi said Wednesday that the products would be available in stores by this Friday and through the CVS website “soon.”

On December 20, 2018, the U.S. Food and Drug Administration completed an evaluation of three generally recognized as safe (GRAS) notices for hemp seed-derived food ingredients. The agency concluded that hulled hemp seed (GRN765), hemp seed protein powder (GRN771), and hemp seed oil (GRN778) are GRAS as they contain only trace amounts of THC and CBD. The GRAS notices are for three different hemp seed-derived ingredients for certain uses including adding them as a source of protein, carbohydrates, oil, and other nutrients to beverages (juices, smoothies, protein drinks, plant-based alternatives to dairy products), soups, dips, spreads, sauces, dressings, plant-based alternatives to meat products, desserts, baked goods, cereals, snacks and nutrition bars. The FDA’s complete release of the GRAS notice can be read here.

NutraLife BioSciences is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). NLBS recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NLBS’s filings with the SEC can be viewed at www.sec.gov. NLBS’s CBD products and information about the Company’s direct sales program can be found online at https://nutrahempcbd.com and by following the company on Instagram.

* The statements in this Release have not been evaluated by the Food and Drug Administration.

* NutraLife’s CBD and nutraceutical products are not intended to diagnose, treat, cure or prevent any disease.

* NutraLife is not affiliated with and has no association with Curaleaf or CVS Health Corp.

Forward-Looking Statements

This communication from NutraLife BioSciences, Inc. (the “Company”) contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife Biosciences, Inc.
6601 Lyons Road
Suite L-6 Coconut Creek
FL  33073 Telephone
Telephone: 888-509-8901
www.Nutralifebiosciences.com

NutraLife Bioscience, Inc. Receives License to Grow and Process Industrial Hemp

Summary: NutraLife Biosciences, Inc. Receives License to Grow and Process Industrial Hemp in  the state of Wisconsin.

NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) has received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state. The Company plans to develop  efficient, cost reducing growing systems and processing technologies for industrial hemp.

Edgar Ward, Founder and CEO of NutraLife commented: “As a company entering the bio life sciences space it is our goal to become vertically integrated as a trusted supplier of raw bulk materials and insure the efficacy and quality of the products produced.”

According to a recent Hemp Industry Daily report, Wisconsin was deemed a ‘new and emerging market’ for hemp and hemp production. The report also names Wisconsin the ‘fastest-moving state yet to allow hemp industry to take root.’ Other up and coming states include California and Virginia, to name a few.

The Company’s in-house products include the NutraHempCBD and NutraSpray brands. The Company manufactures 100% of its in-house products at its FDA approved facility in accordance with GMP.  The Company developed its first branded products in 2013. The Company’s product development, testing and research is conducted by four chemists under the supervision of Mr. Ward.

NutraLife Biosciences, Inc., formerly known as NutraFuels, Inc., (“NutraLife” or the “Company”) also recently announced a name change to NutraLife BioSciences, Inc. and new stock trading symbol, NLBS. The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

 

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

 

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraLife BioSciences, Inc., (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraLife Biosciences, Inc. (OTCQB: NLBS) Receives Contract to Provide Its Technologies and Delivery System for Pharmaceutical Products by cGMP Pharmacy

NutraLife Biosciences enters into a contract with a cGMP pharmacy to provide its technologies and a delivery system for pharmaceutical products.

NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) announces it has signed an agreement with Orlando Pharmacy, a USP 797 compliant compounding pharmacy, to provide its technologies and an innovative delivery system for pharmaceutical products

Craig Sicinski, a pharmacist and owner of Orlando Pharmacy and a board advisor to BioHealth Technologies, a CBD and nutraceutical AI PAAS (Platform As A Service) company commented, “We are thrilled to have this new agreement with with NutraLife and to use its technologies and delivery system in our pharmaceutical products. Our shared goal is to discover new innovations within the life sciences space.”

Edgar Ward, CEO and Founder of NutraLife Biosciences stated, “this is a great opportunity for us to expand our technologies and delivery systems into the Pharmaceutical marketplace. Pharmacist Craig Sicinski of Orlando Pharmacy is in-line with our mission to develop the most effective and efficient delivery systems. With Orlando Pharmacy, we are taking our first steps into the pharmaceutical marketplace.”

“We are excited to explore the possibilities for our technologies and processes in the life sciences space and to have our technologies and delivery systems used in the creation of compounded pharmaceutical products  by the pharmacists at Orlando Pharmacy, an experienced cGMP facility. We look forward to a long and rewarding relationship with Mr. Sicinski and his team at Orlando Pharmacy”, said Mr. Ward.

Orlando Pharmacy is a USP 797 compliant pharmacy that has been serving the Orlando community for more than 60 years. Orlando Pharmacy is designated as a Good Neighbor Pharmacy, a network of more than 4,5000 independent pharmacies.  Orlando Pharmacy prides themselves on their reputation for credibility, integrity, and always going the extra mile to meet the needs of its customers and patients.”

Nutralife Biosciences, Inc. operates a multifaceted life sciences company. Since 2013, NutraLife’s manufacturing facility has been registered with the FDA and operated in accordance with the GMP standard. The Company manufactures and distributes private label and branded nutraceutical and wellness products. Through its subsidiaries, Precision Analytic Testing, Inc., and PhytoChem Technologies, Inc., the Company provides bulk material analytical, identity, potency and purity testing of raw hemp, hemp cultivation, raw bulk material extraction and processing. In February of 2019, the Company’s subsidiary, NutraDerma Technologies, Inc. acquired its first product, a patented all natural dermal patch designed to ward off insects including mosquitoes.

NutraLife Sciences is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). NLBS recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NLBS’s filings with the SEC can be viewed at www.sec.gov. NLBS’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication from NutraLife BioSciences, Inc. (the “Company”) contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

 

Contact:

 

NutraLife Biosciences, Inc.

6601 Lyons Road

Suite L-6 Coconut Creek

FL  33073 Telephone

Telephone: 888-509-8901

www.Nutralifebiosciences.com

St. Patrick’s Day

To read this press release on OTCMarkets.com visit:

NutraHempCBD Announces March Promo Is For You, And Your Pet Too!

 

NutraHempCBD celebrates St. Patrick’s Day with 40% off a 600 mg Full Spectrum Tincture and a Pet Wellness Tincture combo!

NutraHempCBD, a line of hemp-derived cannabidiol (CBD) products from the life sciences company, Nutralife Biosciences, Inc. (Nutralife or “the Company”) is celebrating St. Patrick’s Day by offering 40% off when you buy a 600mg Full Spectrum Tincture and a Pet Wellness Tincture! The promo price will be $80, that’s reduced from the original $135 sticker price.

NutraHempCBD full spectrum cannabidiol formula has 600 mg of hemp-derived CBD in every bottle and has been hailed by consumers as a convenient way to reap the benefits of full-spectrum cannabidiol. This NutraHempCBD formula comes in an easy-to-dose spray instead of an oily dropper and customers can expect a delivery of 14 mg of full-spectrum hemp-derived CBD per six-spray serving. The hemp utilized is grown on a USDA Certified Organic farm and the formula is flavored with stevia leaf extract for a superior taste.

The NutraPet Drops are for your furry friends! Our pet CBD products are designed to provide  anti-inflammatory and overall wellness factors. Our pet-friendly formula comes in convenient CBD drops that can be added directly to your pet’s favorite food or treat. The drops deliver 8.33 mg hemp-derived full spectrum CBD per serving and just like our human spray the CBD is from hemp grown on an organic farm.

NutraLife Biosciences, Inc., formerly known as NutraFuels, Inc., (“NutraLife” or the “Company”) also recently announced a name change to NutraLife BioSciences, Inc. and  new stock trading symbol, NLBS. The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact: NutraLife Biosciences, Inc.

6601 Lyons Road

Suite L-6 Coconut Creek

FL  33073 Telephone

888-509-8901

www.Nutralifebiosciences.com

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

Coconut Creek, FL, March 05, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. (the “Company”) is pleased to announce a name change to NutraLife  BioSciences, Inc. and a new stock trading symbol, NLBS.  The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations. Commencing March 6, 2019, the Company’s common shares will trade with the stock ticker symbol “NLBS”.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

Coconut Creek, FL, Feb. 28, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc., fka NutraLife Biosciences, Inc. (“the Company” or “NutraFuels”) (OTCQB: NTFU) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems.

“We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer,” said Edgar Ward, CEO and Founder of NutraFuels.

The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.

The Company manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company’s product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, the Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. The Company’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraFuels, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.